Partner Content Partner Content Highly Potent Active Pharmaceutical Ingredients - Under 2 We... HPAPI 2018
Partner Content Partner Content SMi’s HPAPI 2018 Conference: Exclusive Interview Released wi... HPAPI 2018
Partner Content Partner Content Introducing the 2nd Annual HPAPI Conference this May 2018 2nd Annual HPAPI Conference this May 2018
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
